I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting 2020-11-09 21:12
I-Mab Announces Upcoming Participation at November Conferences 2020-10-28 20:00
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020-10-27 20:05
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency 2020-09-30 20:00
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma 2020-09-21 20:00
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer 2020-09-18 04:05
I-Mab Announces Upcoming Participation at September Conferences 2020-09-08 20:00
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium 2020-09-04 19:01
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy 2020-09-04 19:00
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update 2020-08-31 19:00
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China 2020-08-17 20:00
I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020 2020-08-06 20:30
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency 2020-08-04 20:17
I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer 2020-07-28 20:22
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million 2020-07-16 04:15
I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II 2020-06-12 20:00
I-Mab Announces Upcoming Participation at June Conferences 2020-05-29 20:00
I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome 2020-05-28 04:05
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme 2020-05-21 20:00
I-Mab Expands Global Presence with New Hong Kong Office 2020-05-20 16:00
1 5 6 7 8 9